CpG island methylation in Schistosoma- and non-Schistosoma-associated bladder cancer

Modern Pathology

Volumn 17, Issue 10, 2004, Pages 1268-1274

  Gutiérrez, Marina I ^a   Siraj, Abdul K ^a   Khaled, Hussein ^b   Koon, Natalie ^c   El Rifai, Wa'El ^c   Bhatia, Kishor ^a,d,e  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b NATIONAL CANCER INSTITUTE   (Egypt)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^d INTERNATIONAL NETWORK FOR CANCER TREATMENT AND RESEARCH   (Belgium)

^e MBC#9816 ^*  (Saudi Arabia)

Author keywords

Bilharziasis; Concurrent hypermethylation; Epigenetics; Infection; Methylator phenotype; Squamous cell carcinoma; Transitional cell carcinoma

Indexed keywords

APC PROTEIN; DEATH ASSOCIATED PROTEIN KINASE; FRAGILE HISTIDINE TRIAD PROTEIN; GLUTATHIONE TRANSFERASE P1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; ONCOPROTEIN; PROTEIN P14; PROTEIN P15; PROTEIN P73; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; BLADDER CANCER; BLADDER EPITHELIUM; CONTROLLED STUDY; CPG ISLAND; DISEASE ASSOCIATION; DNA METHYLATION; EGYPT; ENDEMIC DISEASE; EPIGENETICS; HUMAN; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCHISTOSOMA; SCHISTOSOMIASIS; SQUAMOUS CELL CARCINOMA; URINARY TRACT CARCINOMA;

ACID ANHYDRIDE HYDROLASES; ADENOMATOUS POLYPOSIS COLI PROTEIN; APOPTOSIS REGULATORY PROTEINS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CADHERINS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CPG ISLANDS; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DNA-BINDING PROTEINS; GENES, TUMOR SUPPRESSOR; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; ISOENZYMES; NEOPLASM PROTEINS; NUCLEAR PROTEINS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; POLYMERASE CHAIN REACTION; RECEPTORS, RETINOIC ACID; SCHISTOSOMIASIS HAEMATOBIA; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 4744370521     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3800177     Document Type: Article

References (36)

1. Badawi AF, Mostafa MH, Probert A, et al. Role of schistosomiasis in human bladder cancer: evidence of association, aetiological factors, and basic mechanisms of carcinogenesis. Eur J Cancer Prev 1995;4:45-59.
2. Ibrahim S. Site distribution of cancer in Egypt: twelve years experience (1970-1981). In: Khogali M, Omar YT, Gjorgor A, Ismail AS, editors. Cancer Prevention in Developing Countries. Pergamon Press: Oxford, UK, 1986, pp. 20-32.
3. Johansson SL, Cohen SM. Epidemiology and etiology of bladder cancer. Semin Surg Oncol 1997;13:291-298.
4. Bedwani R, el-Khwsky F, Renganathan E, et al. Schistosomiasis and the risk of bladder cancer in Alexandria, Egypt. Br J Cancer 1998;77:1186-1189.
5. Matanoski GM, Elliott EA. Bladder cancer epidemiology. Epidemiol Rev 1981;3:203-229.
6. Khaled HM. Bladder cancer and Bilharziasis today. Cancer J 1993;6:65-71.
7. El-Bolkainy MN, Mokhtar NM, Ghoneim MA, et al. The impact of schistosomiasis on the pathology of bladder carcinoma. Cancer 1981;48:2643-2648.
8. Tricker AR, Mostafa MH, Spiegelhalder B, et al. Urinary nitrate, nitrite and N-nitroso compounds in bladder cancer patients with schistosomiasis (bilharzia). IARC Sci Publ 1991;105:178-181.
9. Ramchurren N, Cooper K, Summerhayes IC. Molecular events underlying schistosomiasis-related bladder cancer. Int J Cancer 1995;62:237-244.
10. Gonzalez-Zulueta M, Shibata A, Ohneseit PF, et al. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder. J Natl Cancer Inst 1995;87:1383-1393.
11. Sandberg AA. Cytogenetics and molecular genetics of bladder cancer: a personal view. Am J Med Genet 2002;115:173-182.
12. Diggle CP, Cruickshank S, Olsburgh JD, et al. Identification of genes up-regulated in urothelial tumors: the 67-Kd laminin receptor and tumor associated tripsin inhibitor. Am J Pathol 2003;163:493-504.
13. Sanchez-Carbayo M, Socci ND, Lozano JJ, et al. Gene discovery in bladder cancer progression using cDNA microarray. Am J Pathol 2003;163:505-516.
14. Weintraub M, Khaled HM, Zekri A, et al. p53 mutations in Egyptian bladder cancer. Int J Oncol 1995;6:1269-1274.
15. Ghaleb AH, Pizzolo JG, Melamed MR. Aberrations of chromosomes 9 and 17 in bilharzial bladder cancer as detected by fluorescence in situ hybridization. Am J Clin Pathol 1996;106:234-241.
16. Wu RL, Osman I, Wu XR, et al. Uroplakin II gene is expressed in transitional cell carcinoma but not in bilharzial bladder squamous cell carcinoma: alternative pathways of bladder epithelial differentiation and tumor formation. Cancer Res 1998;58:1291-1297.
17. Muscheck M, Abol-Enein H, Chew K, et al. Comparison of genetic changes in schistosome-related transitional and squamous bladder cancers using comparative genomic hybridization. Carcinogenesis 2000;21:1721-1726.
18. Rifai W, Kamel D, Larramendy ML, et al. DNA copy number changes in Schistsoma associated bladder cancer. Am J Pathol 2000;156:871-878.
19. Khaled HM, Aly MS, Magrath IT. Loss of Y chromosome in bilharzial bladder cancer. Cancer Genet Cytogenet 2000;117:32-36.
20. Costello JF, Fruhwald MC, Smiraglia DJ, et al. Aberrant CpG-island methylation has non-random and tumor-type-specific patterns. Nat Genet 2000;25:132-138.
21. Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumors. J Pathol 2002;196:1-7.
22. Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 2001;61:8659-8663.
23. Chan MWY, Chan LW, Tang NLS, et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clinical Cancer Res 2002;8:464-470.
24. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002;21:5427-5440.
25. Issa J-P. Methylation and prognosis: of molecular clocks and hypermethylator phenotypes. Clin Cancer Res 2003;9:2879-2881.
26. Badawi AF, Cooper DP, Mostafa MH, et al. Promutagenic methylation damage in liver DNA of mice infected with Schistosoma mansoni. Carcinogenesis 1993;14:653-657.
27. Esteller M. Relevance of DNA methylation in the management of cancer. Lancet Oncol 2003;4:351-358.
28. Gutiérrez MI, Siraj AK, Bhargava M, et al. Concurrent methylation of multiple genes in childhood ALL: correlation with phenotype and molecular subgroup. Leukemia 2003;17:1845-1850.
29. Chan MW, Chan LW, Tang NL, et al. Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients. Int J Cancer 2003;104:611-616.
30. Ribeiro-Filho LA, Franks J, Sasaki M, et al. CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer. Mol Carcinogenesis 2002;34:187-198.
31. Dominguez G, Carballido J, Silva J, et al. p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin Cancer Res 2002;8:980-985.
32. Chang LL, Yeh WT, Yang SY, et al. Genetic alterations of p16INK4a and p14ARF genes in human bladder cancer. J Urol 2003;170:595-600.
33. Markl ID, Cheng J, Liang G, et al. Global and gene specific epigenetic patterns in human bladder cancer genomes are relatively stable in vivo and in vitro over time. Cancer Res 2001;61:5875-5884.
34. Esteller M, Corn PG, Baylin SB, et al. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-3229.
35. Shen L, Ahuja N, Shen Y, et al. DNA methylation and environmental exposures in human hepatocellular carcinoma. J Natl Cancer Inst 2002;94:755-761.
36. Ambinder RF, Robertson KD, Tao Q. DNA methylation and the Epstein-Barr virus. Semin Cancer Biol 1999;9:369-375.